Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.-MedSci.cn

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Yau, T; Kang, YK; Kim, TY; El-Khoueiry, AB; Santoro, A; Sangro, B; Melero, I; Kudo, M; Hou, MM; Matilla, A; Tovoli, F; Knox, JJ; He, AR; El-Rayes, BF; Acosta-Rivera, M; Neely, J; Shen, Y; Baccan, C; Dela Cruz, CM; Hsu, C

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务